News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

January 9, 2023

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/ Refractory Acute Myeloid Leukemia

December 22, 2022

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

December 12, 2022

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

December 10, 2022

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

December 10, 2022

Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

December 1, 2022

Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress

November 15, 2022

Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting

November 7, 2022

Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022

November 4, 2022

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE^®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

November 3, 2022

Events

All

Scientific

Investors

28Mar

Innate Killer Summit

March 28 - 30, 2023 (San Diego, USA)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/ Refractory Acute Myeloid Leukemia

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress

Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting

Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE^®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

Events

Innate Killer Summit